Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Azora Therapeutics, Inc. (DE) (AZR)

Azora Therapeutics names Matthew Davidson CEO, replacing Cary Claiborne

Neutral Impact 4 of 5 leadership Written later

Azora Therapeutics, formerly Adial Pharmaceuticals, appointed Matthew Davidson, Ph.D. as President and Chief Executive Officer effective October 28, 2026, succeeding Cary J. Claiborne, whose employment was terminated. The board also appointed Celia Economides as Chief Financial Officer, succeeding Vinay Shah, and Julie Saiki, Ph.D. as Chief Strategy Officer. Stockholders approved increasing authorized common stock from 100,000,000 to 500,000,000 shares and the name change, with the new ticker AZR expected to begin trading October 29, 2026.

Key points

  • Matthew Davidson, Ph.D. appointed President and CEO effective October 28, 2026; Cary J. Claiborne's employment terminated, subject to a release for severance.
  • Celia Economides appointed CFO, succeeding Vinay Shah, whose employment was terminated effective October 28, 2026.
  • Authorized common stock increases from 100,000,000 to 500,000,000 shares; the amendment takes effect 12:01 AM Eastern on October 29, 2026.
  • Stockholders approved issuance of up to 23,561,896 shares on exercise of milestone pre-funded and incentive warrants, among other proposals.

The filing

CompanyAzora Therapeutics, Inc. (DE) (AZR)
Form8-K, current report
Filed with the SECOct 28, 2026, 4:30 PM ET
Accession number0001213900-26-113337

Items reported: 5.02 Director / Officer Change5.03 Bylaw / Charter Amendment5.07 Shareholder Vote Results7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:38 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 28, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.